Fulltext present in this item

Thumbnail
Fulltext: 71126.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
Author(s): Leen, W.G. ; Weemaes, C.M.R. ; Verbeek, M.M. ; Willemsen, M.A.A.P. ; Rotteveel, J.J.
Publication year: 2008
Source: Pediatric Neurology, vol. 39, iss. 3, (2008), pp. 213-217
ISSN: 0887-8994
DOI: http://dx.doi.org/10.1016/j.pediatrneurol.2008.05.015
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/71126   https://hdl.handle.net/2066/71126

Display more details
Subject: DCN 1: Perception and Action
DCN 2: Functional Neurogenomics
DCN 3: Neuroinformatics
N4i 1: Pathogenesis and modulation of inflammation
NCEBP 11: Alzheimer Centre
UMCN 3.1: Neuromuscular development and genetic disorders
UMCN 3.2: Cognitive neurosciences
UMCN 4.1: Microbial pathogenesis and host defense
Organization: Neurology
Paediatrics
Journal title:
Pediatric Neurology
Volume: vol. 39
Issue: iss. 3
Page start: p. 213
Page end: p. 217
Abstract:
We describe 2 children with postinfectious opsoclonus-myoclonus syndrome. Although the patients initially responded to monotherapy with methylprednisolone, intravenous immunoglobulins, or rituximab, they manifested persistent neurologic deficits and relapsing signs. Treatment with rituximab in combination with intravenous immunoglobulin, however, resulted in significant longterm clinical improvement.

This item appears in the following Collection(s)

Browse

Statistics